Stay updated on GR-MD-02 for NASH Cirrhosis: Safety & Efficacy Clinical Trial

Sign up to get notified when there's something new on the GR-MD-02 for NASH Cirrhosis: Safety & Efficacy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GR-MD-02 for NASH Cirrhosis: Safety & Efficacy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:16:22.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dosage of GR MD 02 in a clinical trial for the treatment of liver fibrosis and resultant portal hypertension in patients with Nash cirrhosis.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:15.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study. The new criteria specify health conditions and prior treatments required for inclusion, such as having a HVPG measurement ≥6 mm Hg and a liver biopsy with cirrhosis due to NASH.
    Difference
    46%
    Check dated 2024-05-22T21:20:34.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:43:27.000Z thumbnail image

Stay in the know with updates to GR-MD-02 for NASH Cirrhosis: Safety & Efficacy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GR-MD-02 for NASH Cirrhosis: Safety & Efficacy Clinical Trial page.